High-dose medroxyprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomised study

Area of Science:

• Oncology
• Urology
• Pharmacology

Background:

• Metastatic prostate cancer progression after first-line hormonal therapy presents a significant clinical challenge.
• Evaluating alternative treatment options is crucial for improving patient outcomes in advanced prostate cancer.

Purpose of the Study:

• To compare the efficacy and safety of high-dose medroxyprogesterone acetate (MPA) versus estramustine in patients with metastatic prostate cancer progressing on prior hormonal treatment.
• To assess progression-free survival, overall survival, remission rates, and treatment-related side effects.

Main Methods:

• A randomized trial involving 105 patients with metastatic prostate cancer.
• Patients were assigned to either high-dose MPA or estramustine.
• Outcomes including survival, remission, and adverse events were monitored.

Main Results:

• No statistically significant difference in progression-free survival or overall survival rates was observed between MPA and estramustine.
• Medroxyprogesterone acetate (MPA) demonstrated a significantly higher rate of remissions (13 vs. 4 patients) compared to estramustine.
• Fewer treatment discontinuations due to side effects were reported in the MPA group (3/51) compared to the estramustine group (8/51).

Conclusions:

• High-dose medroxyprogesterone acetate (MPA) appears to offer a better response rate and improved tolerability compared to estramustine in this patient population.
• Despite differences in response rates, overall survival did not differ significantly between the two treatment arms.
• MPA may be a viable treatment option for metastatic prostate cancer patients who have progressed on first-line hormonal therapy, considering its favorable side effect profile.